tirzepatide pregnancy safety guidelines Does Cause Birth Defects? Evidence and Guidance tirzepatide before pregnancy and Planning

The SURMOUNT-1 trial, which evaluated tirzepatide specifically for weight management in patients with obesity, demonstrated even more impressive results: average weight reductions of 15% (10 mg dose) to 20.9% (15 mg dose) of initial body weight over 72 weeks

Protocols using IGF-1 LR3 at 80 mcg/day paired with follistatin-344 at 200 mcg every 3 days show optimal satellite cell proliferation without oversaturating IGF-1 receptors or depleting follistatin-binding capacity

Peterson, J., Schubert, D., Bemben, M., Campbell, J., and Black, C

A landmark study by Ng et al

The duration of treatment varies based on individual goals and response

A: Thats still being studied